Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Monotherapy and in Combination With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

NCT06074497 is registered in ClinicalTrials.gov with Kangabio AUSTRALIA LTD PTY as lead sponsor.

NCT NCT06074497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06074497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Monotherapy and in Combination With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
Lead sponsor
Kangabio AUSTRALIA LTD PTY
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
May 30, 2028
Enrollment
54 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors